Patients belonging to category 7 (requiring ECMO or vasopressor support). <br/ >Pregnant subjects. <br/ >Patients participating in other clinical trials. <br/ >Known case of any psychiatric illness. <br/ >Treating physician assessed high likelihood of mortality in 72 hours of randomization. <br/ >Subjects who have received steroids dose of over 0.4 mg/kg/day of dexamethasone or 2mg/kg/day of methylprednisolone for over 2 day in past 14 days. <br/ >Co-existing condition mandating the use of high dose steroids. <br/ >Life threatening comorbidities like <br/ >a. CKD requiring dialysis. <br/ >b. Life threatening new onset arrythmia. <br/ >c. Hypotension. <br/ >d. Evidence or suspicion of active bacterial infection. <br/ >e. Evidence or suspicion of acute onset renal or liver failure <br/ >f. Child C category of chronic liver disease. <br/ >g. Co-existing autoimmune disease requiring immunosuppressive drugs. <br/ >h. Concurrent use of tocilizumab/baricitinib/itolizumab. <br/ >

Patients belonging to category 7 (requiring ECMO or vasopressor support). <br/ >Pregnant subjects. <br/ >Patients participating in other clinical trials. <br/ >Known case of any psychiatric illness. <br/ >Treating physician assessed high likelihood of mortality in 72 hours of randomization. <br/ >Subjects who have received steroids dose of over 0.4 mg/kg/day of dexamethasone or 2mg/kg/day of methylprednisolone for over 2 day in past 14 days. <br/ >Co-existing condition mandating the use of high dose steroids. <br/ >Life threatening comorbidities like <br/ >a. CKD requiring dialysis. <br/ >b. Life threatening new onset arrythmia. <br/ >c. Hypotension. <br/ >d. Evidence or suspicion of active bacterial infection. <br/ >e. Evidence or suspicion of acute onset renal or liver failure <br/ >f. Child C category of chronic liver disease. <br/ >g. Co-existing autoimmune disease requiring immunosuppressive drugs. <br/ >h. Concurrent use of tocilizumab/baricitinib/itolizumab. <br/ >

N/A

N/A

Patients belonging to category 7 (requiring ECMO or vasopressor support). <br/ >Pregnant subjects. <br/ >Patients participating in other clinical trials. <br/ >Known case of any psychiatric illness. <br/ >Treating physician assessed high likelihood of mortality in 72 hours of randomization. <br/ >Subjects who have received steroids dose of over 0.4 mg/kg/day of dexamethasone or 2mg/kg/day of methylprednisolone for over 2 day in past 14 days. <br/ >Co-existing condition mandating the use of high dose steroids. <br/ >Life threatening comorbidities like <br/ >a. CKD requiring dialysis. <br/ >b. Life threatening new onset arrythmia. <br/ >c. Hypotension. <br/ >d. Evidence or suspicion of active bacterial infection. <br/ >e. Evidence or suspicion of acute onset renal or liver failure <br/ >f. Child C category of chronic liver disease. <br/ >g. Co-existing autoimmune disease requiring immunosuppressive drugs. <br/ >h. Concurrent use of tocilizumab/baricitinib/itolizumab. <br/ >

Patients belonging to category 7 (requiring ECMO or vasopressor support). <br/ >Pregnant subjects. <br/ >Patients participating in other clinical trials. <br/ >Known case of any psychiatric illness. <br/ >Treating physician assessed high likelihood of mortality in 72 hours of randomization. <br/ >Subjects who have received steroids dose of over 0.4 mg/kg/day of dexamethasone or 2mg/kg/day of methylprednisolone for over 2 day in past 14 days. <br/ >Co-existing condition mandating the use of high dose steroids. <br/ >Life threatening comorbidities like <br/ >a. CKD requiring dialysis. <br/ >b. Life threatening new onset arrythmia. <br/ >c. Hypotension. <br/ >d. Evidence or suspicion of active bacterial infection. <br/ >e. Evidence or suspicion of acute onset renal or liver failure <br/ >f. Child C category of chronic liver disease. <br/ >g. Co-existing autoimmune disease requiring immunosuppressive drugs. <br/ >h. Concurrent use of tocilizumab/baricitinib/itolizumab. <br/ >